

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Cost Comparison Appraisal**

**Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1**

**ID6618**

**Final Stakeholder List**

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>SpringWorks Therapeutics</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>Brain and Spine Foundation</li> <li>Brain Charity</li> <li>Childhood Tumour Trust</li> <li>Genetic Alliance UK</li> <li>Nerve Tumour UK</li> <li>Neurological Alliance</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>Association of Anaesthetists</li> <li>Association of British Neurologists</li> <li>Association of Cancer Physicians</li> <li>Association of Genetic Nurses &amp; Counsellors</li> <li>Association of Surgeons of Great Britain and Ireland</li> <li>British Association of Paediatric Surgeons</li> <li>British Geriatrics Society</li> <li>British Neuro-Oncology Society</li> <li>British Neuropathological Society</li> <li>British Paediatric Neurology Association</li> <li>British Pharmacological Society</li> <li>British Society for Gene and Cell Therapy</li> <li>British Society for Genetic Medicine</li> <li>Institute of Neurology</li> <li>Primary Care and Community Neurology Society</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health - Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>Neurological Alliance of Scotland</li> <li>NHS Confederation</li> <li>NHS Wales Joint Commissioning Committee</li> <li>Scottish Medicines Consortium</li> <li>Wales Neurological Alliance</li> <li>Welsh Government</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>Alexion (selumetinib)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>Brain Research UK</li> <li>Children's &amp; Young People's Cancer Association (Children's Cancer &amp; Leukaemia Group)</li> <li>Cochrane Cystic Fibrosis &amp; Genetic Disorders Group</li> <li>Genomics England</li> <li>MRC Clinical Trials Unit</li> <li>National Hospital for Neurology and Neurosurgery</li> </ul>

Provisional stakeholder list for the evaluation of mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 ID6618  
Issue date: January 2026

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Paediatrics &amp; Child Health</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• Guy's and St Thomas' NHS Foundation Trust</li> <li>• Manchester University NHS Foundation Trust</li> <li>• NHS England</li> </ul>	<ul style="list-style-type: none"> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.